Maze Therapeutics, Inc. financial data

Symbol
MAZE on Nasdaq
Location
171 Oyster Point Boulevard, Suite 300, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.9M shares
Common Stock, Shares, Outstanding 43.9M shares
Common Stock, Value, Issued 44K USD
Weighted Average Number of Shares Outstanding, Basic 43.8M shares +1733%
Weighted Average Number of Shares Outstanding, Diluted 43.8M shares +915%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 28.1M USD +43.8%
General and Administrative Expense 8.37M USD +41.8%
Operating Income (Loss) -36.5M USD -126%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -33.7M USD -124%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -33.7M USD -124%
Earnings Per Share, Basic -0.77 USD/shares -113%
Earnings Per Share, Diluted -0.77 USD/shares -124%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 265M USD +51.1%
Assets, Current 271M USD
Property, Plant and Equipment, Net 6.01M USD
Operating Lease, Right-of-Use Asset 21.7M USD
Other Assets, Noncurrent 3.57M USD
Assets 304M USD
Accounts Payable, Current 3.67M USD
Employee-related Liabilities, Current 5.68M USD
Liabilities, Current 19.9M USD
Operating Lease, Liability, Noncurrent 20.3M USD
Other Liabilities, Noncurrent 1.09M USD
Liabilities 41.3M USD
Retained Earnings (Accumulated Deficit) -425M USD
Stockholders' Equity Attributable to Parent 262M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 262M USD
Liabilities and Equity 304M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.5M USD -25.9%
Net Cash Provided by (Used in) Financing Activities 127M USD +418%
Net Cash Provided by (Used in) Investing Activities -299K USD -7.17%
Common Stock, Shares Authorized 500M shares
Common Stock, Shares, Issued 43.9M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 266M USD +50.8%
Depreciation 684K USD -28%
Payments to Acquire Property, Plant, and Equipment 299K USD +7.17%
Operating Lease, Liability, Current 4.72M USD
Preferred Stock, Shares Authorized 10M shares
Additional Paid in Capital 687M USD
Share-based Payment Arrangement, Expense 3.24M USD +51.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares